MOLOGIC

Updated 346 days ago
Private Limited Company
  • Active - 04784437 (CH)
  • Age: 20 years
  • ID: 50639547/9
BEDFORD TECHNOLOGY PARK THURLEIGH, BEDFORDSHIRE, MK44 2YA
• 72110 - Research and experimental development on biotechnology
Mologic was founded in 2003 by Paul Davis and Mark Davis. Paul Davis has deep knowledge of lateral flow technology as the only remaining practicing scientist from the original technology development team (Davis, May and Prior - 1989), that led to the creation of UniPath and the Clearblue brand for home pregnancy testing. Paul's knowledge of rapid diagnostics and its commercial application is unsurpassed. During his 30+ year tenure with Unilever, Paul innovated across the fields of professional healthcare, consumer healthcare and agriculture, as witnessed by his extensive patent filing history... Bringing skills together for real impact, we work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care... At Global Access Diagnostics (GADx) we have the experience and the technology to create and produce rapid tests in any quantity, and manufacture and distribute tests world-wide. Founded by one of the creators of the..
Also known as: MOLOGIC LTD.
Registration numbers: 04784437 (CH), 4784437 (W)
Primary location: Thurleigh United Kingdom
Associated domains: covi-go.com, mologic.co.uk, mologic.org, mologicdx.com
  • 0
  • 0
Interest Score
5
HIT Score
0.20


CTO

Chairman

Chief Commercial Officer

UK Company Data

Company number
04784437
Account category
FULL
Account ref. day
30
Account ref. month
6
Accounts next due date
2024-03-31
Accounts last made up date
2022-06-30
Returns next due date
2016-07-28
Returns last made up date
2015-06-30
Num. mort. charges
1
Num. mort. outstanding
1
Num. mort. part. satisfied
0
Num. mort. satisfied
0
Num. gen. partners
0
Num. lim. partners
0
Domain
globalaccessdx.com

Actual
www.globalaccessdx.com

IP
3.67.141.185, 3.127.73.216, 18.193.36.153

Status
OK

Category
Company
0 comments Add a comment